Effect of Polyethylene Glycol Loxenatide Treatment on Body Weight in Patients With Type 2 Diabetes With Different Body Mass Index: A Retrospective Real‐World Study
Peng Xu, Chen Dong, Xingzhi Xu, Kuanyong Zheng, Qinghua Liu, Yale Duan, Zhizhen Hu, Liya Bao, Benping Zhang · 2026
Read Effect of Polyethylene Glycol Loxenatide Treatment on Body Weight in Patients With Type 2 Diabetes With Different Body Mass Index: A Retrospective Real‐World Study by Peng Xu, Chen Dong, Xingzhi Xu, Kuanyong Zheng, Qinghua Liu, Yale Duan, Zhizhen Hu, Liya Bao, Benping Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13150479.txt.
Description
Peng Xu and co-authors report a real-world study from two thousand twenty-six on a weekly diabetes injection and body weight across body sizes. The drug, a long-acting GLP-1 medicine called PEG-loxenatide, lowers blood sugar, but its weight effects in normal-weight patients were unclear. The team compared it with a daily pill class known to cut weight.
After matching, sixty-eight patients per group were followed for twenty-four weeks. The injection group lost about one point two kilograms on average, the pill group about two point four. About a third of injection patients lost at least five percent of body weight, and blood sugar control improved clearly. Weight loss ran strongest in obese patients for both drugs. The authors conclude the injection trims weight modestly across body mass ranges.
Catalog record
| CREATOR | Peng Xu, Chen Dong, Xingzhi Xu, Kuanyong Zheng, Qinghua Liu, Yale Duan, Zhizhen Hu, Liya Bao, Benping Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |